# 119-hr-8857: Next GEN Act of 2026

119-hr-8857, Next GEN Act of 2026, is a 119th Congress bill sponsored by Rep. Morelle, Joseph D. [D-NY-25] (D-NY); status introduced; PRIA reads it as touching household money (as of 2026-09-21).

- Canonical: https://policyrisk.com/legislation/119-hr-8857
- As of: 2026-09-21
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-hr-8857
- Congress: 119
- Title: Next GEN Act of 2026
- Status: introduced
- Introduced: 2026-05-15
- Sponsor: Rep. Morelle, Joseph D. [D-NY-25] (D-NY)
- Cosponsors: 4
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-09-21

## Summary

This bill would create a new legal category for "engineered cyclic peptides" and **set an 11-year reference point** for those products in the Drug Price Negotiation Program. It defines which molecules count and ties the rule to future negotiation lists. - Drug makers of engineered cyclic peptides: would be evaluated against an 11-year reference point instead of the usual 7-year point when the program applies timing rules. - What counts as an engineered cyclic peptide: the bill limits the category to polymers mainly made of amino acids, with a single cyclic structure, no more than 40 amino acids, discovered via genetically encoded library screening, not naturally derived, and self‑administered (oral, inhaled, or similar). - When it takes effect: the change would apply to lists published under section 1192(a) on or after the date of enactment.

## Cosponsors (4)

- Rep. Gottheimer, Josh [D-NJ-5] (D-NJ), 2026-05-15T00:00:00.000Z
- Rep. Pfluger, August [R-TX-11] (R-TX), 2026-05-15T00:00:00.000Z
- Rep. Kean, Thomas H. [R-NJ-7] (R-NJ), 2026-05-15T00:00:00.000Z
- Rep. Davis, Donald G. [D-NC-1] (D-NC), 2026-08-27T00:00:00.000Z

## Provisions PRIA read

- Later Medicare price talks for some drugs: cost, low. If enacted, this bill would change how Medicare's Drug Price Negotiation Program treats some peptide drugs. It would use an 11-year negotiation reference period instead of the usual 7 years for products called "engineered cyclic peptides." The bill would define those peptides with six rules: mainly…

## Related bills

- 119-hr-9211: Jewish American Security Act
- 119-hr-1262: Mikaela Naylon Give Kids a Chance Act
- 119-hr-842: Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
- 119-hr-2853: Combating Organized Retail Crime Act of 2025
- 119-hr-1422: Enhanced Iran Sanctions Act of 2025
- 119-hr-9250: Great American Outdoors Act 250

## Sources
- [119-hr-8857 on Congress.gov](https://www.congress.gov/bill/119th-congress/house-bill/8857)

## Related
- [119-hr-9211: Jewish American Security Act](https://policyrisk.com/legislation/119-hr-9211)
- [119-hr-1262: Mikaela Naylon Give Kids a Chance Act](https://policyrisk.com/legislation/119-hr-1262)
- [119-hr-842: Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage A…](https://policyrisk.com/legislation/119-hr-842)
- [119-hr-2853: Combating Organized Retail Crime Act of 2025](https://policyrisk.com/legislation/119-hr-2853)
- [119-hr-1422: Enhanced Iran Sanctions Act of 2025](https://policyrisk.com/legislation/119-hr-1422)
- [119-hr-9250: Great American Outdoors Act 250](https://policyrisk.com/legislation/119-hr-9250)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-hr-8857 (as of 2026-09-21).